Omega-3 Fatty Acids & Depression vs. Genetics: EPA-to-DHA Ratio (2024 Study)

by

Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA), may reduce the risk of major depressive disorder (MDD), but causality remains uncertain due to potential pleiotropic mechanisms.

Highlights:

  1. Genetic Evidence for Omega-3 & Depression: The study used two-sample Mendelian randomization to investigate the causality between genetically predicted omega-3 fatty acid levels and major depression, finding a protective effect of omega-3, especially EPA.
  2. Role of EPA: Eicosapentaenoic acid (EPA) showed the largest effect size, suggesting it plays a significant role in reducing MDD risk.
  3. Robustness to Lipid Correlations: The protective effect of omega-3 remained robust even when accounting for biologically correlated lipids such as cholesterol and triglycerides.
  4. FADS Gene Cluster Influence: The FADS gene cluster emerged as a key driver of the omega-3 effect on MDD, though potential pleiotropic effects could not be fully ruled out.

Source: Translational Psychiatry (2024)

Major Findings: Omega-3 Fatty Acids & Depression vs. Genetics (2024)

1. Protective Effect of Omega-3 Fatty Acids

Genetically predicted higher levels of omega-3 fatty acids were associated with a reduced risk of major depressive disorder (MDD).

Details:

  • Odds Ratio (OR): The odds of developing MDD decreased with higher genetically predicted total omega-3 fatty acid levels (ORIVW 0.96 per standard deviation (SD) increase, 95% CI 0.93–0.98, p=0.003).
  • Specific Fatty Acids: Eicosapentaenoic acid (EPA) had the largest protective effect (OREPA 0.92 per SD increase, 95% CI 0.88–0.96, p=0.0002), suggesting a significant role in reducing MDD risk.
  • Long-Chain Omega-3s: Both EPA and docosahexaenoic acid (DHA) showed stronger protective effects compared to total omega-3 levels, indicating the importance of long-chain omega-3s in depression prevention.

2. Robust After Adjustment for Biologically Correlated Lipids

The protective effect of omega-3 fatty acids remained robust even after adjusting for other biologically correlated lipids.

Details:

  • Multivariable MR (MVMR) Models: The protective effect of omega-3 fatty acids on MDD was consistent even when accounting for high- and low-density cholesterol and triglycerides.
  • Statistical Significance: The effect of total omega-3 remained significant in MVMR analyses (ORIVW 0.93, 95% CI 0.90–0.97, p=0.0001), highlighting the independent role of omega-3s.

3. Role of the FADS Gene Cluster

The FADS gene cluster was a major contributor to the observed effects of omega-3 fatty acids on major depressive disorder (MDD).

Details:

  • Genetic Influence: The FADS SNP (rs174564) explained a significant proportion of the variance in omega-3 measures and was crucial in driving the protective effect.
  • Effect Attenuation: Omitting the FADS SNP in ‘leave-one-out’ analyses reduced the effect sizes and widened the confidence intervals, though the protective direction remained consistent.

4. Colocalization Analyses

Colocalization analyses suggested a shared causal variant between omega-3 fatty acid levels and MDD.

Details:

  • Shared Variant: Genetic colocalization indicated that the same genetic variant might influence both omega-3 levels and MDD risk (PPA for omega-3 and MDD was high, suggesting a shared causal variant).
  • Genomic Confounding: While colocalization supported a shared causal variant, the presence of multiple causal variants or linkage disequilibrium (LD) confounding could not be fully excluded.

5. Implications for EPA and DHA

EPA showed a stronger protective effect against MDD compared to DHA, highlighting the importance of EPA dose and ratio in supplementation strategies.

Details:

  • Comparative Effects: MVMR analyses indicated a more substantial protective effect for EPA (OREPA 0.93, 95% CI 0.88–0.97, p=0.002) than for DHA (ORDHA 0.98, 95% CI 0.92–1.04, p=0.46).
  • Supplementation Guidelines: These findings support the emphasis on higher EPA doses and appropriate EPA ratios in current supplementation guidelines for preventing MDD.

How to Take Omega-3 Fatty Acids for Depression (Based on this MR Study)

Disclaimer: Talk to a medical doctor to verify safety before supplementing with omega-3 fatty acids for depression.

1. Dosage & Ratio

EPA:

  • Dose: 1-2 grams (g) of eicosapentaenoic acid (EPA) per day.
  • Rationale: The study found that EPA showed the largest protective effect against major depressive disorder (MDD).

DHA:

  • Dose: While DHA is important, the study suggests focusing on EPA for its stronger association with reduced MDD risk.
  • Supplementary Dose: Up to 1 gram (g) of docosahexaenoic acid (DHA) per day can be included, maintaining the correct ratio.

EPA-to-DHA ratio:

  • Minimum Ratio: 2:1 (EPA to DHA)
  • Rationale: A higher EPA to DHA ratio is recommended based on meta-analytical evidence and the study’s findings that EPA has a more pronounced effect on reducing depressive symptoms.

2. Format of Supplements

Fish Oil Capsules:

  • Description: The most common and widely available form, typically containing both EPA and DHA.
  • Recommendation: Look for capsules that specify the EPA and DHA content to ensure they meet the recommended dosage and ratio.

Concentrated EPA Supplements:

  • Description: Designed to provide higher concentrations of EPA, making it easier to achieve the optimal dosage.
  • Recommendation: These supplements are ideal for individuals needing targeted intervention for depression.

Algal Oil:

  • Description: A plant-based alternative suitable for vegetarians and vegans, can be enriched with EPA.
  • Recommendation: Ensure the algal oil supplement contains sufficient EPA to meet the recommended dosage.
See also  Moral Luck in Science: The Ethical Implications of He Jiankui’s CRISPR Experiment

3. Administration Details

Consistent timing: Take the supplement daily to maintain consistent levels of omega-3 fatty acids in the bloodstream.

With Meals: Taking supplements with meals can improve absorption and reduce gastrointestinal discomfort.

4. Verify Quality & Purity

Certification: Opt for supplements that have been third-party tested for purity and potency. Certifications from reputable organizations like the International Fish Oil Standards (IFOS) or the Global Organization for EPA and DHA Omega-3s (GOED) are indicators of quality.

Purity: Ensure the supplement is free from contaminants such as heavy metals, dioxins, and polychlorinated biphenyls (PCBs).

Study Overview: Omega-3 Fatty Acids vs. Major Depressive Disorder & Genetics (2024)

The study sought to determine whether genetically predicted higher levels of omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are protective against MDD.

Sample

Exposure Data: Genetic variants associated with circulating omega-3 and omega-6 fatty acids were selected from the UK Biobank (UKBB), involving 115,078 participants of European ancestry.

Outcome Data: Data on MDD and recurrent MDD were obtained from the Psychiatric Genomics Consortium (PGC) genome-wide association studies (GWAS):

  • MDD GWAS: Included 430,775 participants (116,209 cases and 314,566 controls).
  • Recurrent MDD GWAS: Included 80,933 participants (17,451 cases and 63,482 controls).

Methods

Mendelian Randomization (MR):

  • Two-Sample MR: Used to estimate the effect of genetically predicted fatty acid levels on the odds of developing MDD and recurrent MDD.
  • Genetic Instruments: Single nucleotide polymorphisms (SNPs) robustly associated with fatty acid levels were selected from GWAS data.

Multivariable MR (MVMR):

  • Purpose: To account for the influence of biologically correlated lipids such as high- and low-density cholesterol and triglycerides.
  • Approach: Adjusted MR models to isolate the independent effect of omega-3 fatty acids on MDD risk.

Genetic Colocalization Analyses:

  • Objective: To explore the presence of a shared underlying causal variant between omega-3 fatty acid levels and MDD.
  • Technique: Estimated the probability of colocalization to determine if the same genetic variants influence both traits.

Sensitivity Analyses:

  • Leave-One-Out Analysis: Assessed the impact of each individual SNP on the overall results.
  • Steiger Filtering: Confirmed the direction of the effect by comparing the variance explained by SNPs in exposure and outcome.

Limitations

  • Sample Overlap: Overlap between the exposure (UKBB) and outcome (PGC MDD) samples could introduce bias.
  • Genomic Confounding: The presence of multiple causal variants or linkage disequilibrium (LD) confounding in the genetic region could not be fully excluded.
  • Pleiotropy: Horizontal pleiotropy, where genetic variants influence the outcome through pathways other than the exposure, could affect the results.
  • Measurement Precision: EPA levels were obtained from a smaller GWAS sample, potentially introducing measurement variability and weak instrument bias.

Why Omega-3 Fatty Acids May Not Help Depression…

While this study suggests a potential protective role of omega-3 fatty acids, particularly eicosapentaenoic acid (EPA), against major depressive disorder (MDD), several limitations prevent us from confirming the degree of benefit or guaranteeing that supplementation will help everyone with depression.

Individual Differences: People may respond differently to omega-3 supplementation due to genetic, dietary, and lifestyle factors. What works for one individual might not work for another, leading to variability in the degree of benefit observed.

Sample Overlap and Bias: The overlap between the exposure and outcome samples could introduce bias, affecting the reliability of the results. This makes it challenging to establish a direct cause-and-effect relationship.

Genomic Confounding: The presence of multiple genetic variants or linkage disequilibrium in the studied region means that other genetic factors might influence both omega-3 levels and MDD, complicating the causal inference.

Complex Metabolic Pathways: Omega-3 fatty acids influence multiple metabolic pathways, and the observed effects on MDD might be due to interactions with other lipids or metabolic processes, rather than a direct effect of omega-3s alone.

Population Specificity: The study primarily involved individuals of European ancestry from the UK Biobank. Results may not be applicable to other populations with different genetic backgrounds and environmental exposures.

Conclusion: Omega-3s & Depression

While this study provides promising evidence that omega-3 fatty acids, particularly EPA, may help reduce the risk of major depressive disorder (MDD), several limitations prevent us from confirming the exact degree of benefit.

Individual variability, potential biases, and complex metabolic interactions mean that omega-3 supplementation might not be effective for everyone with depression.

Additionally, the findings may not be generalizable across all populations.

Therefore, further research is essential to validate these results and understand the specific contexts in which omega-3 supplementation could be most beneficial for mental health.

References